High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150

References

• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Armitage J. O., Shipp M. Lymphoma classification: From R.E.A.L. to W.H.O. and beyond. Princ. Pract. Oncol. Updates 1999; 13(3)1–14
   Google Scholar
• Anderson T., Bender R. A., Fisher R. I., DeVita V. T., Chabner B. A., Berard C. W., Norton L., Young R. C. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treat. Rep. 1977; 61: 1057–1066
   PubMedGoogle Scholar
• Glick J. H., Barnes J. M., Ezdinli E. Z., Berard C. W., Orlow E. L., Bennett J. M. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981; 58: 920–925
   PubMed Web of Science ®Google Scholar
• Mac Manus M. P., Hoppe R. T. Overview of treatment of localized low-grade lymphomas. Hematol. Oncol. Clin. N. Am. 1997; 11: 901–918
   PubMed Web of Science ®Google Scholar
• Connors J. M., Klasa R. Treatment of follicular lymphoma. Curr. Opin. Oncol. 1998; 10: 392–395
   PubMedGoogle Scholar
• Lister T. A., Cullen M. H., Beard M. E., Brearley R. L., Whitehouse J. M., Wrigley P. F., Stansfeld A. G., Sutcliffe S. B., Malpas J. S., Crowther D. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br. Med. J. 1978; 1: 533–537
   PubMed Web of Science ®Google Scholar
• Hoppe R. T., Kushlan P., Kaplan H. S., Rosenberg S. A., Brown B. W. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981; 58: 592–598
   PubMed Web of Science ®Google Scholar
• Portlock C. S., Rosenberg S. A., Glatstein E., Kaplan H. S. Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial. Blood 1976; 47: 747–756
   PubMed Web of Science ®Google Scholar
• Portlock C. S., Rosenberg S. A. Chemotherapy of the non-Hodgkin's lymphomas: the Stanford experience. Cancer Treat. Rep. 1977; 61: 1049–1055
   PubMedGoogle Scholar
• Peterson B. A., Frizzera B., Anderson J., Bloomfield C. D., Gottlieb A. J. Response of low grade lymphoma to cyclophosphamide or cyclophosphamide, adriamycin, vincristine, prednisone, bleomycin (CAVPB) prednisone, bleomycin (CAVPB). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1985; 822a
   Google Scholar
• McLaughlin P., Hagemeister F. B., Swan F. J., Cabanillas F., Pate O., Romaguera I. E., Rodriguez M. A., Redman J. R., Keating M., Phase I. study of combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J. Clin. Oncol. 1994; 12: 575–579
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Grillo-Lopez A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Zasadny K. R., Francis I. R., Fenper M. C., Ross C. W., Milik A. W., Estes J., Tuck M., Regan D., Fisher S., Glenn S. D., Wahl R. L. Iodine-131-anti-B1 radioimmunofherapy for B-cell lymphoma. J. Clin. Oncol. 1996; 14: 1974–1981
   PubMed Web of Science ®Google Scholar
• Czuczman M. S., Grillo-Lopez A. J., White C. A., Saleh M., Gordon L., LoBuglio A. F., Jonas C., Klippenstein D., Dallaire B., Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A. S., Neuberg D., Roy D. C., Blake K. W., Woo S. D., Grossbard M. L., Rabinowe S. N., Coral F., Freeman G. J., et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Bierman P. J., Vose J. M., Anderson J. R., Bishop M. R., Kessinger A., Armitage J. O. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 1997; 15: 445–450
   PubMed Web of Science ®Google Scholar
• Lichtman S. M., Ratain M. J., van Echo D. A., Rosner G., Egorin M. J., Budman D. R., Vogelzang N. J., Norton L., Schilsky R. L. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J. Natl. Cancer Inst. 1993; 85: 1319–1326
   PubMed Web of Science ®Google Scholar
• Peterson B. A., Petroni G. R., Oken M. M., Johnson J. L., Barcos M., Cooper M. R. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: an intergroup phase III trial (CALGB 8691 and EST 7486). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1997; 16: 48a
   Google Scholar
• Cheson B. D., Homing S. J., Coiffier B., Shipp M. A., Fisher R. L., Connors J. M., Lister T. A., Vose I., Grillo-Lopez A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddemann W., Castellino R., Harris N. L., Armitage J. O., Carter W., Hoppe R., Canellos G. P. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Romaguera J. E., McLaughlin P., North L., Dixon D., Silvermintz K. B., Gamsey L. A., Velasquez W. S., Hagemeister F. B., Cabanillas F. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J. Clin. Oncol. 1991; 9: 762–769
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Ptojec. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329: 987–994t
   PubMed Web of Science ®Google Scholar
• Foussard C., Desablens B., Sensebe L., Francois S., Milpied N., Deconinck E., Delwail V., Dugay J., Lamy T., Ghandour C., Le Mevel A., Maisonneuve H., Casassus P., Colombat P. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III—IV patients. The GOELAMS Group, France. Ann. Oncol. 1997; 8: 49–52
   PubMed Web of Science ®Google Scholar
• Levine E. G., Arthur D. C., Frizzera G., Peterson B. A., Hurd D. D., Bloomfield CD. There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. Blood 1985; 66: 1414–1422
   PubMed Web of Science ®Google Scholar
• Offit K., Wong G., Filippa D. A., Tao Y., Chaganti R. S. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 1991; 77: 1508–1515
   PubMed Web of Science ®Google Scholar
• Bakhshi A., Wright J. J., Graninger W., Seto M., Owens J., Cossman J., Jensen J. P., Goldman P., Korsmeyer S. J. Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc. Natl. Acad. Sci. USA 1987; 84: 2396–2400
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A., Woo S. D., Blake K., Shu R. S., Freeman G., Longtine J. A., Pinkus G. S., Nadler L. M. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Gribben J. G., Neuberg D., Mauch P., Soiffer R. J., Anderson K. C., Pandite L., Robertson M. J., Kroon M., Ritz J., Nadler L. M. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–2786
   PubMed Web of Science ®Google Scholar
• Morel P., Laporte J. P., Noel M. P., Lopez M., Douay L., Fouillard L., Detourmignies L., Dupriez B., Lesage S., Isnard F., et al. Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 1995; 9: 576–582
   PubMed Web of Science ®Google Scholar
• Adkins J. C., Peters D. H., Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005–1037
   PubMed Web of Science ®Google Scholar
• Canfield V. A., Vose J., Guiney P., Bennett B., Nichols C. 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas. Leuk. Lymph. 1997; 24: 335–339
   PubMed Web of Science ®Google Scholar